Precision Sensing, SPC

Meet Mr. DeWitt, our multi-talented Chief Engineer at Precision Sensing, SPC! As both a Licensed Professional Electrical Engineer (PE/EE) and a Licensed Professional Mechanical Engineer (PE/ME), Mr. DeWitt brings his extensive expertise to every project he leads. With over two decades of experience, he’s at the forefront of developing cutting-edge technologies that drive our industry forward. His dedication and innovative spirit have been instrumental in shaping the future of our engineering solutions. Outside of work, Mr. DeWitt enjoys spending time outside with his golden retrievers!  Connect with Mr. DeWitt to learn more about his exciting work!  #EngineeringExcellence #Innovation #EmployeeSpotlight #PrecisionSensingSPC

In today's business landscape, success isn't just measured by profitability—it's also about the impact we make on society. We are proud of our dedication to extending the lives of cancer patients while maintaining a commitment to being socially and environmentally responsible. #SocialPurpose #Innovation #Leadership #CancerResearch

Traditionally known for its harmful effects, lead is now gaining positive recognition in cancer treatment. Lead-212, in particular, is showing great promise with its α-particle emissions that can irreversibly damage cancer cells. With a shorter half-life and easier synthesis compared to actinium-225, lead-212 is becoming a preferred option for many in the field. Companies are investing heavily to harness the potential of this powerful isotope, marking a significant shift in cancer therapy. The future of α therapies looks promising! https://lnkd.in/eSJPySNa #CancerResearch #Radiopharmaceuticals #Lead212 #MedicalInnovation

Understanding Why Patients Miss Imaging Appointments: New Insights from UCI Researchers: Radiology researchers at the University of California, Irvine, have delved into the reasons behind missed imaging appointments, revealing critical insights. Their analysis, covering nearly 300 patients from four imaging centers, highlights two significant factors: 📊 **Financial Hardship:** A staggering 44% of patients cited financial difficulties as a barrier. 🏥 **Health-Related Social Needs:** 33% of patients faced at least one health-related social need. Let’s work together to ensure no patient has to miss critical imaging appointments due to avoidable hardships. https://lnkd.in/eMqK3JbW #Healthcare #Radiology #PatientCare #SocialNeeds #FinancialHardship #MedicalResearch #ClinicalImaging

One more step in the right direction for precision medicine and improved oncology therapeutic options!

There are some exciting insights from a recent interview with Dr. Alexandra Sokolova from Oregon Health & Science University, conducted by Andrea Miyahira of the Prostate Cancer Foundation. Dr. Sokolova’s team presented groundbreaking research on genomic alterations associated with responses to Lutetium PSMA (Pluvicto) in metastatic castration-resistant prostate cancer. They found that alterations in FGFR, MYC, and CDK12 genes are linked to lower PSA50 responses and that tumor suppressor gene alterations (TP53, RB1, PTEN) were associated with poorer overall survival and progression-free survival. This research has the potential to better predict patient response to Pluvicto and enhance personalized treatment strategies! See comments for the link to the interview. #ProstateCancer #CancerResearch #PrecisionMedicine #Radiotheranostics #Oncology

The development of a groundbreaking chelator that can significantly reduce off-target toxicity in PSMA radiopharmaceutical therapy was announced at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting. This innovation improves the bond between the radioactive metal ion and the PSMA-targeting antibody, making therapy safer and more effective for patients. Dr. Carolyn Anderson from the University of Missouri shared, "A better chelator means that the radiometal accumulates mostly in the tumor, reducing toxicity." #ProstateCancer #Radiopharmaceuticals #MedicalInnovation #SNMMI2024 #Healthcare Link to the full article in the comments.

Steve Reed, a 77-year-old living with metastatic prostate cancer since 1998, faced significant challenges with chemotherapy. After 18 cycles, the side effects became unbearable. In January 2023, his oncologist suggested a new theranostic drug, Pluvicto (177Lu-PSMA-617). This treatment targets cancer cells with minimal side effects, offering Reed a better quality of life. Since starting Pluvicto, he experienced virtually no side effects and resumed activities he loves, including travel. Theranostics is revolutionizing cancer treatment, providing new hope for patients with advanced stages of the disease. #CancerTreatment #Theranostics #Pluvicto #MedicalInnovation #Oncology https://lnkd.in/efiKbxgJ

We're proud to share that the PRRT Vest has been successfully fitted on our first patient at the prestigious Fred Hutchinson Cancer Center! This marks a significant milestone in our journey to make impactful advancements in cancer care. With therapeutic applications targeting internal radiopharmaceutical therapies (RPT), currently for neuroendocrine (NET) and prostate cancers, the PRRT Vest signifies a paradigm shift in cancer treatment. By providing improved efficacy and personalized care, we're redefining standards and bringing hope to countless individuals battling cancer. #PRRTVest #CancerTreatment #Radiotheranostics #Innovation

The DUONEN multicenter study aims to develop a personalized dosimetry-based treatment algorithm for Peptide Receptor Radionuclide Therapy (PRRT) in patients with well-differentiated neuroendocrine tumors (NETs). This randomized, phase III study compares the efficacy of personalized therapy with mixed [177Lu]Lu- and [90Y]Y-DOTA-TATE to standard therapy with [177Lu]Lu-DOTA-TATE. Dosimetry is used to optimize radiation dose delivery to tumor tissue while ensuring safety of critical organs. Initial results indicate that personalized dosimetry affects individual PRRT doses in each treatment cycle, with stable disease, partial response, and complete response observed in evaluated patients. The study is funded by the Medical Research Agency. https://lnkd.in/e9eke4Qe #RadiopharmaceuticalTherapy